These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. Liao BC; Lin CC; Lee JH; Yang JC J Biomed Sci; 2016 Dec; 23(1):86. PubMed ID: 27912760 [TBL] [Abstract][Full Text] [Related]
23. [Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs]. Asami K Gan To Kagaku Ryoho; 2014 May; 41(5):533-8. PubMed ID: 24916999 [TBL] [Abstract][Full Text] [Related]
24. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836 [TBL] [Abstract][Full Text] [Related]
25. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122 [TBL] [Abstract][Full Text] [Related]
26. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. Zhang K; Yuan Q J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005 [TBL] [Abstract][Full Text] [Related]
27. Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Singh M; Jadhav HR Drug Discov Today; 2018 Mar; 23(3):745-753. PubMed ID: 29031620 [TBL] [Abstract][Full Text] [Related]
28. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Yasuda H; Kobayashi S; Costa DB Lancet Oncol; 2012 Jan; 13(1):e23-31. PubMed ID: 21764376 [TBL] [Abstract][Full Text] [Related]
29. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Marquez-Medina D; Popat S Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834 [TBL] [Abstract][Full Text] [Related]
30. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357 [TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Jorge SE; Kobayashi SS; Costa DB Braz J Med Biol Res; 2014 Nov; 47(11):929-39. PubMed ID: 25296354 [TBL] [Abstract][Full Text] [Related]
33. Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy. Ghafoor Q; Baijal S; Taniere P; O'Sullivan B; Evans M; Middleton G Pathol Oncol Res; 2018 Oct; 24(4):723-731. PubMed ID: 29270776 [TBL] [Abstract][Full Text] [Related]
34. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. De Luca A; Normanno N Curr Drug Targets; 2010 Jul; 11(7):851-64. PubMed ID: 20388064 [TBL] [Abstract][Full Text] [Related]
35. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer. Nagano T; Tachihara M; Nishimura Y Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691 [TBL] [Abstract][Full Text] [Related]
36. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803 [TBL] [Abstract][Full Text] [Related]
37. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862 [TBL] [Abstract][Full Text] [Related]
38. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963 [TBL] [Abstract][Full Text] [Related]
39. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer]. Ni L; Nie L Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178 [TBL] [Abstract][Full Text] [Related]
40. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC. Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]